Alivus Life Sciences (BOM:543322) EV-to-EBIT : 18.71 (As of Jun. 01, 2025)

Alivus Life Sciences EV-to-EBIT Chart

Alivus Life Sciences Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															14.56	17.72	21.87	20.27	19.34

Competitive Comparison of Alivus Life Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alivus Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's EV-to-EBIT falls into.

Alivus Life Sciences EV-to-EBIT Calculation

Alivus Life Sciences's EV-to-EBIT for today is calculated as:

Alivus Life Sciences's current Enterprise Value is ₹122,826 Mil.
Alivus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,565 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences  (BOM:543322) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alivus Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Alivus Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹126,970 Mil.
Alivus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,565 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alivus Life Sciences Business Description